Did you mean fatal Valproate Spectrum Disorder?
Lord Hunt of Kings Heath: To ask Her Majesty's Government why those with Fetal Valproate Spectrum Disorder are required to re-apply for (1) Personal Independence Payment, and (2) Disability Living Allowance, given that the condition is lifelong and does not present changing symptoms.
Lord Hunt of Kings Heath: To ask Her Majesty's Government what assessment they have made of the (1) value, and (2) use, of the Condition Insight Report for Valproate in enabling (a) Personal Independence Payment, and (b) Disability Living Allowance, assessors to understand Fetal Valproate Spectrum Disorder.
Lord Hunt of Kings Heath: To ask Her Majesty's Government how many people with Fetal Valproate Spectrum Disorder have been refused the award of (1) Personal Independence Payment, or (2) Disability Living Allowance, over the last 12 months.
Cat Smith: To ask the Secretary of State for Work and Pensions, how many people with fetal valproate spectrum disorder have been refused the award of (a) personal independence payment and (b) disability living allowance in the last 12 months.
Cat Smith: To ask the Secretary of State for Work and Pensions, what impact the Condition Insight Report for Valproate has had on personal independence payment decisions for people with fetal valproate spectrum disorder since its introduction in August 2020.
Ben Lake: To ask the Secretary of State for Work and Pensions, for what reason people with fetal valproate spectrum disorder, which is a life-long disability, are required to re-apply for personal independence payment and disability living allowance.
Cat Smith: To ask the Secretary of State for Health and Social Care, what steps the Government is taking to increase awareness of fetal valproate spectrum disorder among health care professionals.
Lord Hunt of Kings Heath: To ask Her Majesty's Government what steps they are taking to (1) support, and (2) care for, those suffering from Fetal Valproate Spectrum Disorder.
Jonathan Reynolds: ...of State for Work and Pensions, whether all assessors at each stage of (a) a personal independence payment assessment and (b) subsequent appeals have access to insight condition reports for fetal valproate spectrum disorder as recommended in the Independent Medicines and Medical Devices Safety Review report.
Christian Wakeford: To ask the Secretary of State for Health and Social Care, with reference to recent World Health Organisation updates and the addition of fetal valproate spectrum disorder to the 11th revision of the International Classification of Diseases, what steps he is taking to (a) integrate that disorder into treatment and (b) ensure its diagnosis on the NHS.
Jonathan Reynolds: To ask the Secretary of State for Health and Social Care, what proportion of patients of child and adult mental health services administered by the NHS have (a) fetal valproate spectrum disorder, (b) fetal valproate syndrome, (c) fetal anti-convulsant syndrome and (d) autistic spectrum disorder primarily caused by valproate in pregnancy.
Jonathan Reynolds: To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the public purse of providing social care for children diagnosed with fetal valproate spectrum disorder as a result of their mother being prescribed valproate in pregnancy in the last year for which data is available.
Emma Hardy: ...State for Health and Social Care, if he will ask the Office for National Statistics to provide the figures for the years from 2013 to 2020 of the number of recorded births of babies diagnosed with fetal valproate spectrum disorder.
Justin Madders: To ask the Secretary of State for Health and Social Care, how many children have been (a) exposed to Valproate in pregnancy, (b) harmed by Valproate in pregnancy and (c) diagnosed with Fetal Valproate Spectrum Disorder, since April 2018.
Cat Smith: To ask the Secretary of State for Health and Social Care, how many children have been (a) exposed to Valproate in pregnancy, (b) harmed by Valproate in pregnancy and (c) diagnosed with Fetal Valproate Spectrum Disorder since April 2018.
Liz Twist: ...that. Secondly, this legislation clearly impacts on the role of the MHRA. At this point, I want to mention the great work of Emma Murphy and Janet Williams, who have worked so hard on the issue of fetal valproate spectrum disorder, to which my hon. Friend the Member for Leicester South (Jonathan Ashworth) referred. They have found that, despite the devastating impact arising from women...
Norman Lamb: ...is, did it know then? These things need to be investigated further. It is important to state what the risks are. Among the general population there is a 2% to 3% risk of foetal abnormality. If valproate is taken during pregnancy, that risk rises to 11%, and possible defects include spina bifida; malformations of the face, including cleft palate; malformations of the skull, limbs and...
Anas Sarwar: ...and may require additional educational support.” In 2011, Sanofi added: “Some babies born to mothers who took Epilim…during pregnancy may develop less quickly than normal or have autistic disorders.” Sanofi therefore recognised in 2005 and 2011 that its drug can have a negative impact on a foetus. Why did that take so long? Research by a group of six academics from the universities...